David P Richman

Title(s)Professor, Med: Neurology
SchoolSchool of Medicine
Address1515 Newton Ct
CA 95618
Phone530-754-5006
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Princeton University, Princeton, NJA.B.06/1965Mathematics
    Johns Hopkins University, Baltimore, MDM.D.06/1969Medicine
    Collapse Awards and Honors
    University of California, Davis2017  - presDistinguished Professor

    Collapse Research 
    Collapse Research Activities and Funding
    Antigen-Specific Treatment of Myasthenia: Chimeric Autoantibody Receptor T Cells
    Muscular Dystrophy Association Sep 1, 2022 - Aug 31, 2025
    Role: Principal Investigator
    Description: Treatment of rat experimental anti-MuSK myasthenia with CAAR T cells
    Treatment of Experimental MuSK Myasthenia Gravis with NMD Pharma Provided Chloride Channel Blocker
    NMD Pharma A21-4380Aug 1, 2022 - Dec 31, 2023
    Exploratory Research on the Safety and Efficacy of MuSK CAAR T cells in Various Models of anti-MuSK
    Cabaletta Bioscience Jan 25, 2021 - Dec 31, 2026
    Role: PI
    Description: Development of CAAR T cell treatment of experimental of anti-MuSK myasthenia in rats
    Antigen-specific treatment of myasthenia gravis: Chimeric autoantibody receptor T cells targeting autoimmune B cells
    NIH/NINDS R21NS104516Jun 15, 2018 - May 31, 2020
    Role: Principal Investigator
    Development of Animal Models of Anti-MuSK Myasthenia
    NIH/NINDS R21NS071325Sep 30, 2010 - Aug 31, 2013
    Role: Principal Investigator
    IX INTERNATIONAL CONFERENCE ON MYASTHENIA GRAVIS
    NIH/NINDS R13NS036137May 1, 1997 - Apr 30, 1998
    Role: Principal Investigator
    STRUCTURE/FUNCTION ANALYSIS OF ACCHR EPITOPES
    NIH/NINDS P01NS024304Jan 1, 1987 - Sep 30, 1992
    Role: Co-Principal Investigator
    PATHOGENIC MECHANISMS IN MYASTHENIA
    NIH/NINDS R01NS019779Jul 1, 1984 - Jun 30, 1997
    Role: Principal Investigator
    ANTIIDIOTYPIC ANTIBODIES IN MYASTHENIA
    NIH/NINDS R01NS015462Jul 1, 1979 - Mar 31, 1996
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Author Correction: Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2024 Dec; 42(12):1923. Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. PMID: 39543316; PMCID: PMC11631755.
      View in: PubMed   Mentions:    Fields:    
    2. Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review. Front Oncol. 2023; 13:1199195. Xiong G, Young RB, Chow H, Maverakis E, Maselli RA, Richman DP, Li T. PMID: 37465116; PMCID: PMC10350685.
      View in: PubMed   Mentions: 1  
    3. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol. 2023 09; 41(9):1229-1238. Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. PMID: 36658341; PMCID: PMC10354218.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    4. Enrichment of serum IgG4 in MuSK myasthenia gravis patients. J Neuroimmunol. 2022 12 15; 373:577978. Vergoossen DLE, Ruiter AM, Keene KR, Niks EH, Tannemaat MR, Strijbos E, Lipka AF, van der Zijde ECJ, van Tol MJD, Bakker JA, Wevers BA, Westerberg E, Borges LS, Tong OC, Richman DP, Illa I, Punga AR, Evoli A, van der Maarel SM, Verschuuren JJ, Huijbers MG. PMID: 36240543.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2022 01 25; 98(4):e376-e389. Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ, NeuroNEXT NN103 BeatMG Study Team. PMID: 34857535; PMCID: PMC8793103.
      View in: PubMed   Mentions: 37     Fields:    
    6. Thymectomy and myasthenia gravis. Proc Natl Acad Sci U S A. 2020 12 22; 117(51):32195-32196. Lisak RP, Richman DP. PMID: 33273117; PMCID: PMC7768708.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    7. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021 01 19; 96(3):114-122. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. PMID: 33144515; PMCID: PMC7884987.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    8. Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open. 2020 09 18; 10(9):e037909. Green JD, Barohn RJ, Bartoccion E, Benatar M, Blackmore D, Chaudhry V, Chopra M, Corse A, Dimachkie MM, Evoli A, Florence J, Freimer M, Howard JF, Jiwa T, Kaminski HJ, Kissel JT, Koopman WJ, Lipscomb B, Maestri M, Marino M, Massey JM, McVey A, Mezei MM, Muppidi S, Nicolle MW, Oger J, Pascuzzi RM, Pasnoor M, Pestronk A, Provenzano C, Ricciardi R, Richman DP, Rowin J, Sanders DB, Siddiqi Z, Soloway A, Wolfe GI, Wulf C, Drachman DB, Traynor BJ. PMID: 32948566; PMCID: PMC7511637.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    9. Muscle-Specific Kinase Myasthenia Gravis. Front Immunol. 2020; 11:707. Borges LS, Richman DP. PMID: 32457737; PMCID: PMC7225350.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimals
    10. Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia. Muscle Nerve. 2019 09; 60(3):292-298. Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, Richman DP, Wu A, Aleš KL, Jacobus LR, Jacobus DP, Guptill JT, DAPPER Study Team. PMID: 31269226; PMCID: PMC7357813.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    11. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma. Clin Lung Cancer. 2019 07; 20(4):e489-e491. Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW. PMID: 31085042.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    12. Reply. Muscle Nerve. 2018 05; 57(5):E130-E131. Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG. PMID: 29406616.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve. 2018 04; 57(4):561-568. Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, Aleš KL, Jacobus DP, Dapper Study Team. PMID: 29280483; PMCID: PMC5900968.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 12; 16(12):976-986. Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R, REGAIN Study Group. PMID: 29066163.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansCTClinical Trials
    15. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia. CPT Pharmacometrics Syst Pharmacol. 2017 09; 6(9):625-634. Thakkar N, Guptill JT, Aleš K, Jacobus D, Jacobus L, Peloquin C, Cohen-Wolkowiez M, Gonzalez D, DAPPER Study Group. PMID: 28623849; PMCID: PMC5613184.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    16. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator. J Stroke Cerebrovasc Dis. 2017 Jun; 26(6):e102-e104. Bissig D, Manjunath R, Traylor BR, Richman DP, Ng KL. PMID: 28416406.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 11 08; 87(19):2067-2068. Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman DP. PMID: 27821567.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective. Eur J Neurol. 2016 11; 23(11):1593-1594. Richman DP. PMID: 27753233.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016 Jul 26; 87(4):419-25. Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. PMID: 27358333; PMCID: PMC4977114.
      View in: PubMed   Mentions: 360     Fields:    Translation:Humans
    20. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology. 2016 Mar 22; 86(12):1159-63. Oskarsson B, Rocke DM, Dengel K, Richman DP. PMID: 26850977; PMCID: PMC4820129.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    21. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10. Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C. PMID: 26569098.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    22. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. PMID: 26662952.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    23. The Future of Research in Myasthenia. JAMA Neurol. 2015 Jul; 72(7):812-4. Richman DP. PMID: 26011044.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    24. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015 Apr; 72(4):396-404. Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA, Marangi G, Abramzon Y, Arepalli S, Chong S, Hernandez DG, Johnson JO, Bartoccioni E, Scuderi F, Maestri M, Gibbs JR, Errichiello E, Chiò A, Restagno G, Sabatelli M, Macek M, Scholz SW, Corse A, Chaudhry V, Benatar M, Barohn RJ, McVey A, Pasnoor M, Dimachkie MM, Rowin J, Kissel J, Freimer M, Kaminski HJ, Sanders DB, Lipscomb B, Massey JM, Chopra M, Howard JF, Koopman WJ, Nicolle MW, Pascuzzi RM, Pestronk A, Wulf C, Florence J, Blackmore D, Soloway A, Siddiqi Z, Muppidi S, Wolfe G, Richman D, Mezei MM, Jiwa T, Oger J, Drachman DB, Traynor BJ. PMID: 25643325; PMCID: PMC4856525.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    25. How clinical trials of myasthenia gravis can inform pre-clinical drug development. Exp Neurol. 2015 Aug; 270:78-81. Rostedt Punga A, Kaminski HJ, Richman DP, Benatar M. PMID: 25592627; PMCID: PMC4466144.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    26. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochim Biophys Acta. 2015 Apr; 1852(4):651-7. Ha JC, Richman DP. PMID: 25486268.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    27. Corrigendum to “Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor” [Mol. Immunol. 58 (2014) 116–131]. Molecular Immunology. 2014 May 1; 59(1):117. Morell MS, Trinh TV, Gudipati GE, Friend FA, Page PN, Agius AM, Richman RD, Fairclough FR. .
      View in: Publisher Site   Mentions:
    28. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. Mol Immunol. 2014 Mar; 58(1):116-31. Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH. PMID: 24333757.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    29. Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. Mult Scler. 2014 Jan; 20(1):57-63. Kim SS, Richman DP, Johnson WO, Hald JK, Agius MA. PMID: 23736535.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    30. Animal models of antimuscle-specific kinase myasthenia. Ann N Y Acad Sci. 2012 Dec; 1274:140-7. Richman DP, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA. PMID: 23252909; PMCID: PMC3915870.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    31. Current pharmacologic management in selected neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012 Nov; 23(4):801-20. Skalsky AJ, Oskarsson B, Han JJ, Richman D. PMID: 23137738.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Dominantly inherited myotonia congenita resulting from a mutation that increases open probability of the muscle chloride channel CLC-1. Neuromolecular Med. 2012 Dec; 14(4):328-37. Richman DP, Yu Y, Lee TT, Tseng PY, Yu WP, Maselli RA, Tang CY, Chen TY. PMID: 22790975; PMCID: PMC3508202.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    33. Treatment of myasthenia gravis based on its immunopathogenesis. J Clin Neurol. 2011 Dec; 7(4):173-83. Kim JY, Park KD, Richman DP. PMID: 22259613; PMCID: PMC3259491.
      View in: PubMed   Mentions: 20  
    34. Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis. Arch Neurol. 2012 Apr; 69(4):434-5. Richman DP. PMID: 22158717; PMCID: PMC3903387.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol. 2012 Apr; 69(4):453-60. Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA. PMID: 22158720; PMCID: PMC3915865.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    36. Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice. J Neurol Sci. 2011 Jul 15; 306(1-2):9-15. Kim SS, Richman DP, Zamvil SS, Agius MA. PMID: 21529843; PMCID: PMC4172440.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    37. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. Cogn Behav Neurol. 2011 Mar; 24(1):40-2. Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V. PMID: 21467920.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008 Aug 05; 71(6):400-6. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP. PMID: 18434638.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    39. Variable phenotypes associated with mutations in DOK7. Muscle Nerve. 2008 Apr; 37(4):448-56. Anderson JA, Ng JJ, Bowe C, McDonald C, Richman DP, Wollmann RL, Maselli RA. PMID: 18161030.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    40. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler. 2005 Oct; 11(5):568-72. O'Connor P, Miller D, Riester K, Yang M, Panzara M, Dalton C, Miszkiel K, Khan O, Rice G, Sheremata W, International Natalizumab Trial Group. PMID: 16193895.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    41. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005 Mar; 20(3):293-7. Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, Shoulson I, Wexler NS, Young AB, Zhao H. PMID: 15584032.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    42. Treatment of autoimmune myasthenia gravis. Neurology. 2004 Sep 28; 63(6):1138-9; author reply 1138-9. Bragdon AC. PMID: 15452326.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Treatment of autoimmune myasthenia gravis. Neurology. 2003 Dec 23; 61(12):1652-61. Richman DP, Agius MA. PMID: 14694025.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    44. Treatment principles in the management of autoimmune myasthenia gravis. Ann N Y Acad Sci. 2003 Sep; 998:457-72. Richman DP, Agius MA. PMID: 14592915.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Agonist-induced transitions of the acetylcholine receptor. Ann N Y Acad Sci. 2003 Sep; 998:101-13. Fairclough RH, Agius MA, Gudipati E, Silvian L, Hamaoka B, Beltzner CC, Lin MY, Chuang AR, Richman DP. PMID: 14592867.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    46. Three forms of immune myasthenia. Ann N Y Acad Sci. 2003 Sep; 998:453-6. Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, Romi F. PMID: 14592914.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    47. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg. 2001 Sep; 122(3):562-8. Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR. PMID: 11547310.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    48. Presynaptic congenital myasthenic syndrome due to quantal release deficiency. Neurology. 2001 Jul 24; 57(2):279-89. Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL. PMID: 11468313.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    49. Differential surface accessibility of alpha(187-199) in the Torpedo acetylcholine receptor alpha subunits. J Mol Biol. 1998 Sep 18; 282(2):317-30. Fairclough RH, Twaddle GM, Gudipati E, Lin MY, Richman DP. PMID: 9735290.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    50. Mapping the mAb 383C epitope to alpha 2(187-199) of the Torpedo acetylcholine receptor on the three-dimensional model. J Mol Biol. 1998 Sep 18; 282(2):301-15. Fairclough RH, Twaddle GM, Gudipati E, Stone RJ, Richman DP, Burkwall DA, Josephs R. PMID: 9735289.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    51. Quality improvement in neurology residency programs. Neurology. 1998 Sep; 51(3):922-3. Weisberg L, Goldberg M. PMID: 9748074.
      View in: PubMed   Mentions:    Fields:    
    52. A role for alpha(187-199) in the conversion of agonist binding energy to the opening of the acetylcholine receptor ion channel. Ann N Y Acad Sci. 1998 May 13; 841:87-92. Fairclough RH, Gudipati E, Lin MY, Twaddle GM, Richman DP, Burkwall DA, Josephs R. PMID: 9668223.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    53. MAb 383C binds to the alpha-subunit of the acetylcholine receptor associated with the high-affinity tubocurarine site. Ann N Y Acad Sci. 1998 May 13; 841:101-3. Lin MY, Twaddle GM, Gudipati E, Richman DP, Fairclough RH. PMID: 9668226.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    54. Antibody effector mechanisms in myasthenia gravis. The complement hypothesis. Ann N Y Acad Sci. 1998 May 13; 841:450-65. Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, Dupont BL, Maselli RA. PMID: 9668274.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    55. Expression and initial characterization of recombinant antiacetylcholine receptor antibodies in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci. 1998 May 13; 841:466-8. Kirvan CA, Zhu S, Richman DP, Agius MA. PMID: 9668275.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    56. Introduction. Annals of the New York Academy of Sciences. 1998 May 1; 841(1):xvii-xviii. RICHMAN RD. .
      View in: Publisher Site   Mentions:
    57. Quality improvement in neurology residency programs. Report of the Quality Improvement Committee of the Association of University Professors of Neurology. Neurology. 1997 Nov; 49(5):1205-7. Bradley WG, Daube J, Mendell JR, Posner J, Richman D, Troost BT, Swift TR. PMID: 9371894.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study. Muscle Nerve. 1997 Oct; 20(10):1284-95. Maselli RA, Ellis W, Mandler RN, Sheikh F, Senton G, Knox S, Salari-Namin H, Agius M, Wollmann RL, Richman DP. PMID: 9324085.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    59. Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity. J Immunol. 1994 Jun 15; 152(12):5997-6002. Mihovilovic M, Donnelly-Roberts D, Richman DP, Martinez-Carrion M. PMID: 8207224.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    60. Myasthenia gravis: pathogenesis and treatment. Semin Neurol. 1994 Jun; 14(2):106-10. Richman DP, Agius MA. PMID: 7984824.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    61. Acquired myasthenia gravis. Immunopathology. Neurol Clin. 1994 May; 12(2):273-84. Richman DP, Agius MA. PMID: 8041342.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    62. Transcervical thymectomy for myasthenia gravis. Ann Thorac Surg. 1994 Jan; 57(1):194-7. DeFilippi VJ, Richman DP, Ferguson MK. PMID: 8279889.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    63. Neuromuscular transmission in amyotrophic lateral sclerosis. Muscle Nerve. 1993 Nov; 16(11):1193-203. Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, Salazar-Grueso EF, Roos RP. PMID: 8105377.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    64. Characterization of the epitope of an antiacetylcholine receptor antibody that inhibits fifty percent of alpha-bungarotoxin binding. Ann N Y Acad Sci. 1993 Jun 21; 681:175-8. Xu Q, Twaddle GM, Richman DP, Fairclough RH. PMID: 7689304.
      View in: PubMed   Mentions:    Fields:    Translation:Cells
    65. Effects of D-penicillamine on multiple immunogenic epitopes of the acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:335-8. Xu Q, Fairclough RH, Richman DP. PMID: 7689309.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    66. An immunogenic self-peptide for T cells in mice with experimental myasthenia. Ann N Y Acad Sci. 1993 Jun 21; 681:1-4. Xu Q, Agius M, Gudipati E, Fairclough RH, Richman DP. PMID: 8357155.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    67. Effector mechanisms of myasthenic antibodies. Ann N Y Acad Sci. 1993 Jun 21; 681:264-73. Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, Fairclough RH. PMID: 8357166.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    68. Molecular structure of a monoclonal antiacetylcholine receptor antibody and of a corresponding monoclonal antiidiotopic antibody. Ann N Y Acad Sci. 1993 Jun 21; 681:274-5. Agius MA, Sanyal B, Richman DP. PMID: 8357167.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    69. Imaging ligand binding sites on the Torpedo acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:113-25. Fairclough RH, Josephs R, Richman DP. PMID: 7689302.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    70. Interaction of antiacetylcholine receptor monoclonal antibodies with the acetylcholine receptor. Ann N Y Acad Sci. 1993 Jun 21; 681:172-4. Xu Q, Fairclough RH, Richman DP. PMID: 7689303.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    71. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies. Muscle Nerve. 1991 Dec; 14(12):1189-92. Maselli RA, Mass DP, Distad BJ, Richman DP. PMID: 1662771.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    72. Inflammation at the neuromuscular junction in myasthenia gravis. Neurology. 1991 Sep; 41(9):1497-504. Maselli RA, Richman DP, Wollmann RL. PMID: 1891103.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    73. Noninflammatory immune mechanisms in diseases of the nervous system. Res Publ Assoc Res Nerv Ment Dis. 1990; 68:55-65. Richman DP, Fairclough RH, Xu Q, Agius MA. PMID: 2183319.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    74. Interaction of nicotinic acetylcholine receptor with two monoclonal antibodies recognizing different epitopes. Biochemistry. 1989 May 16; 28(10):4222-9. Chinchetru MA, Marquez J, Garcia-Borron JC, Richman DP, Martinez-Carrion M. PMID: 2475163.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    75. Effects of a monoclonal anti-acetylcholine receptor antibody on the avian end-plate. J Physiol. 1989 Apr; 411:271-83. Maselli RA, Nelson DJ, Richman DP. PMID: 2614725; PMCID: PMC1190524.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    76. In vitro blockade of neuromuscular transmission by monoclonal anti-acetylcholine receptor antibodies. Ann N Y Acad Sci. 1988; 540:523-4. Maselli RA, Jow B, Richman DP, Nelson DJ. PMID: 2849901.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    77. Monoclonal anti-idiotopic antibodies against myasthenia-inducing anti-acetylcholine receptor monoclonal antibodies. Preponderance of nonparatope-directed antibodies affecting antigen binding. J Immunol. 1988 Jan 01; 140(1):62-8. Agius MA, Geannopoulos CJ, Fairclough RH, Richman DP. PMID: 3257231.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    78. Chronic experimental autoimmune myasthenia gravis induced by monoclonal antibody to acetylcholine receptor: biochemical and electrophysiologic criteria. J Immunol. 1987 Jul 01; 139(1):73-6. Gomez CM, Richman DP. PMID: 3035025.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    79. Refractoriness to a second episode of experimental myasthenia gravis. Correlation with AChR concentration and morphologic appearance of the postsynaptic membrane. J Immunol. 1987 May 15; 138(10):3269-75. Corey AL, Richman DP, Agius MA, Wollmann RL. PMID: 3494763.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    80. Monoclonal antibodies as probes of the alpha-bungarotoxin and cholinergic binding regions of the acetylcholine receptor. J Biol Chem. 1987 Apr 15; 262(11):4978-86. Mihovilovic M, Richman DP. PMID: 3558382.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    81. Human x human hybridomas from patients with myasthenia gravis: possible tools for idiotypic therapy for myasthenia. Ann N Y Acad Sci. 1987; 505:155-67. Blair DA, Mihovilovic M, Agius MA, Fairclough RH, Richman DP. PMID: 3500665.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    82. Sharing of epitopes by bacteria and the nicotinic acetylcholine receptor: a possible role in the pathogenesis of myasthenia gravis. Ann N Y Acad Sci. 1987; 505:451-60. Stefansson K, Dieperink ME, Richman DP, Marton LS. PMID: 2446557.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    83. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal anti-idiotopic antibody. J Immunol. 1986 Oct 01; 137(7):2195-8. Agius MA, Richman DP. PMID: 3489757.
      View in: PubMed   Mentions: 7     Fields:    Translation:AnimalsCells
    84. Monoclonal antibodies to acetylcholine receptor secreted by human x human hybridomas derived from lymphocytes of a patient with myasthenia gravis. Immunol Invest. 1986 Jun; 15(4):351-64. Blair DA, Richman DP, Taves CJ, Koethe S. PMID: 3759150.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    85. Multiple sclerosis: activated cells in cerebrospinal fluid in acute exacerbations. Ann Neurol. 1985 Dec; 18(6):722-5. Noronha A, Richman DP, Arnason BG. PMID: 3841270.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    86. Use of monoclonal antiacetylcholine receptor antibodies to investigate the macrophage inflammation of acute experimental myasthenia gravis: refractoriness to a second episode of acute disease. Neurology. 1985 Oct; 35(10):1455-60. Corey AL, Richman DP, Shuman CA, Gomez CM, Arnason BG. PMID: 3875805.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    87. Shared antigens on acetylcholine receptor and bacterial proteins. N Engl J Med. 1985 Aug 08; 313(6):389-90. PMID: 2409443.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    88. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol. 1985 Jul; 135(1):234-41. Gomez CM, Richman DP. PMID: 3873489.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    89. Effect of myasthenia serum and anti-acetylcholine receptor monoclonal antibody on the distributions of T-cell subsets in myasthenia patients and normal subjects. Asian Pac J Allergy Immunol. 1985 Jun; 3(1):30-6. Chiu HC, Hsieh KH, Hung TP, Richman DP, Arnason BG. PMID: 3925962.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    90. Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. Possible role in the pathogenesis of myasthenia gravis. N Engl J Med. 1985 Jan 24; 312(4):221-5. Stefansson K, Dieperink ME, Richman DP, Gomez CM, Marton LS. PMID: 2578213.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    91. Treatment of myasthenia gravis. J Neurol. 1985; 232(4):202-3. Richman DP. PMID: 4045512.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    92. Modification of alpha-bungarotoxin and cholinergic ligand-binding properties of Torpedo acetylcholine receptor by a monoclonal anti-acetylcholine receptor antibody. J Biol Chem. 1984 Dec 25; 259(24):15051-9. Mihovilovic M, Richman DP. PMID: 6511786.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    93. A cholinergic receptor site on murine lymphocytes with novel binding characteristics. Life Sci. 1984 Dec 10; 35(24):2459-69. Atweh SF, Grayhack JJ, Richman DP. PMID: 6334799.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    94. A noncholinergic site-directed monoclonal antibody can impair agonist-induced ion flux in Torpedo californica acetylcholine receptor. Proc Natl Acad Sci U S A. 1984 Dec; 81(24):7999-8003. Donnelly D, Mihovilovic M, Gonzalez-Ros JM, Ferragut JA, Richman D, Martinez-Carrion M. PMID: 6096872; PMCID: PMC392281.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    95. Simultaneous cell surface phenotype and cell cycle analysis of lymphocytes by flow cytometry. J Histochem Cytochem. 1984 Aug; 32(8):821-6. Noronha A, Richman DP. PMID: 6205045.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    96. Myelin-associated glycoprotein in human retina. Nature. 1984 Feb 9-15; 307(5951):548-50. Stefansson K, Molnar ML, Marton LS, Molnar GK, Mihovilovic M, Tripathi RC, Richman DP. PMID: 6198592.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    97. Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor. Acta Neuropathol. 1984; 63(2):131-43. Gomez CM, Wollmann RL, Richman DP. PMID: 6610275.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    98. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A. 1983 Jul; 80(13):4089-93. Gomez CM, Richman DP. PMID: 6575398; PMCID: PMC394206.
      View in: PubMed   Mentions: 33     Fields:    Translation:Animals
    99. Mevalonic acid in conjunction with help from neutrophils induces DNA synthesis and cell cycling in human peripheral blood lymphocytes. Cell Immunol. 1982 Sep 15; 72(2):248-62. Yachnin S, Richman DP. PMID: 7151179.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    100. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May; 11(5):456-62. Dropcho EJ, Richman DP, Antel JP, Arnason BG. PMID: 6980619.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    101. Myasthenia induced by monoclonal anti-acetylcholine receptor antibodies: clinical and electrophysiological aspects. Ann Neurol. 1981 Jun; 9(6):563-8. Burres SA, Crayton JW, Gomez CM, Richman DP. PMID: 6167199.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    102. Monoclonal hybridoma anti-acetylcholine receptor antibodies: antibody specificity and effect of passive transfer. Ann N Y Acad Sci. 1981; 377:97-109. Gomez CM, Richman DP, Burres SA, Arnason BG, Berman PW, Fitch FW. PMID: 6978667.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    103. Nicotinic acetylcholine receptor on human lymphocytes. Ann N Y Acad Sci. 1981; 377:427-35. Richman DP, Antel JP, Burns JB, Arnason BG. PMID: 6951484.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    104. Studies on the pathophysiology of chronic D-penicillamine-induced myasthenia. Ann N Y Acad Sci. 1981; 377:640-51. Burres SA, Kanter ME, Richman DP, Arnason BG. PMID: 6951489.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    105. Detection of in vivo stimulated cerebrospinal-fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980 Sep 25; 303(13):713-7. Noronha AB, Richman DP, Arnason BG. PMID: 6157088.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    106. Reduced T-lymphocyte cell reactivity as a function of human aging. Cell Immunol. 1980 Aug 15; 54(1):184-92. Antel JP, Oger JJ, Dropcho E, Richman DP, Kuo HH, Arnason BG. PMID: 6967772.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    107. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature. 1980 Aug 14; 286(5774):738-9. Richman DP, Gomez CM, Berman PW, Burres SA, Fitch FW, Arnason BG. PMID: 7412861.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    108. Lymphocyte cell-cycle analysis by flow cytometry. Evidence for a specific postmitotic phase before return to G0. J Cell Biol. 1980 May; 85(2):459-65. Richman DP. PMID: 6154712; PMCID: PMC2110606.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    109. Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes. Proc Natl Acad Sci U S A. 1979 Sep; 76(9):4632-5. Richman DP, Arnason BG. PMID: 291991; PMCID: PMC411633.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    110. Monoclonal antibodies against purified nicotinic acetylcholine receptor. Biochem Biophys Res Commun. 1979 May 28; 88(2):575-82. Gomez CM, Richman DP, Berman PW, Burres SA, Arnason BG, Fitch FW. PMID: 465055.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    111. Penicillamine-induced myasthenic responses in the guinea pig. Muscle Nerve. 1979 May-Jun; 2(3):186-90. Burres SA, Richman DP, Crayton JW, Arnason BG. PMID: 228188.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    112. Cellular immunity to acetylcholine receptor in myasthenia gravis: relationship to histocompatibility type and antigenic site. Neurology. 1979 Mar; 29(3):291-6. Richman DP, Antel JP, Patrick JW, Arnason BG. PMID: 571972.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    113. Lymphocyte function and the role of regulator cells in multiple sclerosis. Neurology. 1978 Sep; 28(9 Pt 2):106-10. Antel JP, Richman DP, Medof ME, Arnason BG. PMID: 309564.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    114. Contrasting defects of T-lymphocyte mitogenic response in multiple sclerosis and myasthenia gravis. Trans Am Neurol Assoc. 1978; 103:191-3. Richman DP, Dropcho EJ, Antel JP, Arnason BG. PMID: 316215.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    115. Letter: Lymphocyte stimulation by acetylcholine receptor in myasthenia gravis. N Engl J Med. 1976 Jul 22; 295(4):226. Malm TM. PMID: 1272356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    116. Cellular immunity in myasthenia gravis. Response to purified acetylcholine receptor and autologous thymocytes. N Engl J Med. 1976 Mar 25; 294(13):694-8. Richman DP, Patrick J, Arnason BG. PMID: 129705.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    117. Immunogenetics and amyotrophic lateral sclerosis. UCLA Forum Med Sci. 1976; (19):151-71. Antel JP, Richman DP, Arnason BG. PMID: 1023469.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    118. Mechanical model of brain convolutional development. Science. 1975 Jul 04; 189(4196):18-21. Richman DP, Stewart RM, Hutchinson JW, Caviness VS. PMID: 1135626.
      View in: PubMed   Mentions: 185     Fields:    Translation:Humans
    119. Lissencephaly and Pachygyria: an architectonic and topographical analysis. Acta Neuropathol. 1975; 31(1):1-12. Stewart RM, Richman DP, Caviness VS. PMID: 1121923.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    120. Cerebral microgyria in a 27-week fetus: an architectonic and topographic analysis. J Neuropathol Exp Neurol. 1974 Jul; 33(3):374-84. Richman DP, Stewart RM, Caviness VS. PMID: 4835115.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    121. Relative frequency of the Hurler and Hunter syndromes. N Engl J Med. 1970 Dec 24; 283(26):1466-8. PMID: 4991513.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    122. Effect of oral contraceptives on experimental demyelinating disease. Arch Neurol. 1969 Jul; 21(1):103-8. Arnason BG, Richman DP. PMID: 4977266.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    123. Effects of estrogen, progestin and combined estrogen-progestin oral contraceptive preparations on experimental allergic encephalomyelitis. Trans Am Neurol Assoc. 1969; 94:54-8. Arnason BG, Richman DP. PMID: 5374490.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    David's Networks
    Concepts (415)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-8-gc1ed69da on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California